CONNECTA Therapeutics has started a Phase 2a clinical trial of [...]
Servier has acquired KER-0193 from Kaerus Bioscience, gaining a potential [...]
Kaerus Bioscience has been granted Orphan Drug Designation and Rare [...]
CONNECTA Therapeutics has started a Phase 2a clinical trial of [...]
Servier has acquired KER-0193 from Kaerus Bioscience, gaining a potential [...]
Kaerus Bioscience has been granted Orphan Drug Designation and Rare [...]